198 related articles for article (PubMed ID: 6814139)
21. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
22. The effect of vaginal administration of low-dose oral contraceptive tablets on human ovulation.
Souka AR; el Sokkary H; Kamel M; Hassan M
Contraception; 1986 Apr; 33(4):365-71. PubMed ID: 3731776
[TBL] [Abstract][Full Text] [Related]
23. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
Cekan SZ; Jia M; Landgren BM; Diczfalusy E
Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
[TBL] [Abstract][Full Text] [Related]
24. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
[TBL] [Abstract][Full Text] [Related]
25. d-Norgestrel concentrations in maternal plasma, milk, and child plasma during administration of oral contraceptives to nursing women.
Nilsson S; Nygren KG; Johansson ED
Am J Obstet Gynecol; 1977 Sep; 129(2):178-84. PubMed ID: 900181
[TBL] [Abstract][Full Text] [Related]
26. Suppression of ovarian function by Microgynon 30 in day 1 and day 5 "starters".
Taylor DR; Anthony FW; Dennis KJ
Contraception; 1986 May; 33(5):463-71. PubMed ID: 3757512
[TBL] [Abstract][Full Text] [Related]
27. Ovulation detection following removal of levonorgestrel subdermal contraceptive implants.
Ismail AA; Anwar MY; Youssef SM; Toppozada M
Contraception; 1987 Mar; 35(3):207-14. PubMed ID: 3111783
[TBL] [Abstract][Full Text] [Related]
28. Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.
Alvarez F; Brache V; Faundes A; Johansson ED; Odlind V; Nash H
Contraception; 1983 Feb; 27(2):123-30. PubMed ID: 6406138
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
Luukkainen T; Heikinheimo O; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
[TBL] [Abstract][Full Text] [Related]
30. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
31. Studies on ovarian function in users of the progestagen only contraceptive pill.
Tayob Y; Guillebaud J; Adams J; Jacobs HS
J Obstet Gynaecol (Lahore); 1986 Apr; 6 Suppl 2():S91-5. PubMed ID: 12315277
[TBL] [Abstract][Full Text] [Related]
32. Long-term reversible contraception with levonorgestrel-releasing Silastic rods.
Roy S; Mishell DR; Robertson DN; Krauss RM; Lacarra M; Duda MJ
Am J Obstet Gynecol; 1984 Apr; 148(7):1006-13. PubMed ID: 6424474
[TBL] [Abstract][Full Text] [Related]
33. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
[TBL] [Abstract][Full Text] [Related]
34. Ovarian function during treatment with high ratio levonorgestrel/ethinyl estradiol as oral contraceptives.
Johansson ED; Elamsson K; Elmestedt U
Gynecol Obstet Invest; 1982; 14(2):97-105. PubMed ID: 6811379
[No Abstract] [Full Text] [Related]
35. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
[TBL] [Abstract][Full Text] [Related]
36. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device.
Nilsson CG; Lähteenmäki PL; Luukkainen T
Fertil Steril; 1984 Jan; 41(1):52-5. PubMed ID: 6420203
[TBL] [Abstract][Full Text] [Related]
37. Factors affecting pituitary gonadotropin function in users of oral contraceptive steroids.
Scott JA; Brenner PF; Kletzky OA; Mishell DR
Am J Obstet Gynecol; 1978 Apr; 130(7):817-21. PubMed ID: 345817
[TBL] [Abstract][Full Text] [Related]
38. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
39. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
[TBL] [Abstract][Full Text] [Related]
40. Three-year experience with NORPLANT subdermal contraception.
Sivin I; Sanchez FA; Diaz S; Holma P; Coutinho E; McDonald O; Robertson DN; Stern J
Fertil Steril; 1983 Jun; 39(6):799-808. PubMed ID: 6406273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
